Efficacy of Vemurafenib

Vemurafenib was compared with the cancer drug dacarbazine in a major study involving 675 patients with melanoma that harbored the BRAF V600 mutation and whose tumors had spread or could not be removed with surgery. Patients will receive either drug until their disease worsens or their treatment becomes too toxic for them. The main measures of effectiveness are how long patients live (overall survival) and how long they live without their disease getting worse (progression-free survival).

The BRAF V600E mutation is detected in approximately40% of melanoma patients, and the BRAF V600K mutation is detected in approximately 5% of melanoma patients. Vemurafenibhas been shown to be effective in extending patients' lives and slowing the progression of the disease. The study showed that patients taking vemurafenib survived an average of 13.2 months, compared with 9.9 months for those taking dacarbazine, and it took an average of 5.3 months for the disease to worsen in the vemurafenib group, compared with 1.6 months in the dacarbazine group.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.